BioWorld

Oct. 4, 2006

View Archived Issues

Biogen Gains Rights To UCB's CDP323 In $200M Partnership

Adding a fifth product to its portfolio of approved and investigational multiple sclerosis therapies, Biogen Idec Inc. agreed to collaborate on CDP323, an oral alpha-4 integrin inhibitor discovered by UCB. (BioWorld Today) Read More

MacroGenics Gets $63M From Government, Mostly For WNV

Read More

In Pandemic Flu, Strong Immune Response May Be Good, Or Not

Read More

Xanthus In-Licenses U.S. Rights To Oral Fludarabine

Read More

Other News To Note

Read More

Clinic Roundup

Read More